- DMD AAV gene therapy
- Different mutations and deletions in dystrophin can cause a patient to have an immune response against expressed micro-dystrophin
- These dystrophin chimeras are designed to avoid neoantigen presentation for a wide range of known dystrophin mutations, reducing potential immune response